4.6 Article

International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease

期刊

MOVEMENT DISORDERS
卷 36, 期 11, 页码 2583-2594

出版社

WILEY
DOI: 10.1002/mds.28706

关键词

Parkinson's disease; MRI; brain; ENIGMA; disease severity

资金

  1. Dowager Countess Eleanor Peel Trust Medical Research Grant
  2. Alzheimer's Disease Neuroimaging Initiative [U01AG02490]
  3. Neurodegeneration in Aging Down Syndrome [U01AG051406]
  4. ZonMw
  5. Michael J. Fox Foundation
  6. New Zealand Neurological Foundation
  7. Health Research Council of New Zealand
  8. Brain Research New Zealand
  9. School of Psychology, Speech and Hearing
  10. Medtronic
  11. Lysosomal Therapeutics
  12. Neuroderm
  13. Parkinson Vereniging
  14. Stichting Parkinson Nederland
  15. Boston Scientific
  16. AbbVie
  17. UCB
  18. Bial
  19. Zambon
  20. NIHR
  21. EPSRC
  22. MRC
  23. Alzheimer's Association [2018-AARG-592081]
  24. Michael J. Fox Foundation [16048, 15581]
  25. Netherlands Organization for Scientific Research (VENI) [91617077]
  26. Alzheimer's Society
  27. EPSRC UK, EU
  28. Italian Ministry of Health [RC 19, RC 20]
  29. New Zealand Brain Research Institute
  30. Michael J. Fox Foundation for Parkinson's Research, NIH
  31. Swiss National Science Foundation [CRSK-3_190817/1, CRSII5_180365, 320030L_170060]
  32. Novartis AG
  33. VIDI grant from The Netherlands Organization for Health Research (ZonMw) [91717306]
  34. MOST [109-2314-B-182-021-MY3, 109-2221-E-182-009-MY3, 106-2314-B-182-018-MY3]
  35. Michael J. Fox Foundation for Parkinson's Research
  36. Alzheimer's Therapeutic Research Initiative (ATRI)
  37. Alzheimer's Disease Cooperative Study (ADCS)
  38. International Parkinson and Movement Disorder Society (IPMDS)
  39. National Institute on Aging (NIA)
  40. Swiss Personalized Health Network [2018DRI10]
  41. Swiss Innovation Council [43087.1]
  42. University of Bern
  43. Biogen [CHE-TYS-18-11,316]
  44. Biogen Inc.
  45. NIH [U01AG024904, R01MH111671]
  46. Swiss National Science Foundation (SNF) [320030L_170060, CRSII5_180365, CRSK-3_190817] Funding Source: Swiss National Science Foundation (SNF)

向作者/读者索取更多资源

The study used a multicenter approach and harmonized analysis methods to investigate brain structure abnormalities in Parkinson's disease patients. They found that patients had thinner cortex in certain regions compared to healthy controls, with differences increasing with disease severity. Poorer cognition was associated with widespread cortical thinning and lower volumes of core limbic structures.
Background Brain structure abnormalities throughout the course of Parkinson's disease have yet to be fully elucidated. Objective Using a multicenter approach and harmonized analysis methods, we aimed to shed light on Parkinson's disease stage-specific profiles of pathology, as suggested by in vivo neuroimaging. Methods Individual brain MRI and clinical data from 2357 Parkinson's disease patients and 1182 healthy controls were collected from 19 sources. We analyzed regional cortical thickness, cortical surface area, and subcortical volume using mixed-effects models. Patients grouped according to Hoehn and Yahr stage were compared with age- and sex-matched controls. Within the patient sample, we investigated associations with Montreal Cognitive Assessment score. Results Overall, patients showed a thinner cortex in 38 of 68 regions compared with controls (d(max) = -0.20, d(min) = -0.09). The bilateral putamen (d(left) = -0.14, d(right) = -0.14) and left amygdala (d = -0.13) were smaller in patients, whereas the left thalamus was larger (d = 0.13). Analysis of staging demonstrated an initial presentation of thinner occipital, parietal, and temporal cortices, extending toward rostrally located cortical regions with increased disease severity. From stage 2 and onward, the bilateral putamen and amygdala were consistently smaller with larger differences denoting each increment. Poorer cognition was associated with widespread cortical thinning and lower volumes of core limbic structures. Conclusions Our findings offer robust and novel imaging signatures that are generally incremental across but in certain regions specific to disease stages. Our findings highlight the importance of adequately powered multicenter collaborations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据